CSL Limited
corporate_fare Company Profile
CSL Limited (OTC:CSLLY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for CSLLY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-04, rated 8/10.
Recent high-impact activity:
- CSL Pays $355M Upfront for Alentis Kidney/Liver Drug in $1.6B Deal
Short Interest & Short Volume
2.07 days to coverFINRA reported short interest of 160,435 shares in CSLLY as of the October 30, 2026 settlement, a 12.2% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 22.4% of CSLLY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.